)
MDxHealth (MDXH) investor relations material
MDxHealth Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q2 2026 revenue reached $27.2 million, up 16% year-over-year and $3.3 million sequentially, marking the largest sequential increase in company history after discontinuing the Resolve UTI/mdx business and focusing on core prostate cancer diagnostics.
The company transitioned all Resolve customers, completed the wind-down of the Plano, Texas lab and Delta Lab, and eliminated a $10.4 million contingent liability.
Integration of ExoDx and sales force restructuring contributed to recovery in tissue-based diagnostics.
Operational discipline and focus on urology and prostate cancer diagnostics are expected to drive a return to positive adjusted EBITDA by year-end.
Raised $20 million in a registered direct placement in August 2026, strengthening the balance sheet.
Financial highlights
Q2 2026 revenue was $27.2 million, up 16% year-over-year; six-month revenue totaled $51.1 million, up 14% year-over-year.
Gross profit for Q2 was $17.9 million (+11% YoY); gross margin declined to 65.7% from 68.6% due to product/test mix.
Operating loss increased to $5.1 million (236% higher YoY); net loss rose 36% to $9.5 million, mainly due to OpEx from the ExoDx acquisition.
Adjusted EBITDA was negative $2.3 million for Q2, compared to positive $1.1 million in Q2 2025; six-month adjusted EBITDA was negative $7.6 million.
Cash and equivalents stood at $19.2 million at quarter-end; a $20 million direct placement post-quarter brings pro forma cash to $39.2 million.
Outlook and guidance
Full-year 2026 revenue guidance reaffirmed at $110–$115 million, representing 20–26% growth over 2025 (excluding Resolve), with expectations to return to adjusted EBITDA profitability by year-end.
Revenue growth is expected to be generally linear in the second half, with some Q3 seasonality.
Management expects accelerated tissue-based growth and sees significant opportunity for further expansion in 2027, driven by AI initiatives and new clinical data.
- Comprehensive prostate cancer diagnostics drive double-digit revenue growth and market expansion.MDXH
Corporate presentation - Comprehensive urology solutions and robust growth drive revenue guidance to $110–115M for 2026.MDXH
Corporate presentation - Exited Resolve UTI business, focusing on prostate cancer diagnostics and AI-driven growth.MDXH
Q1 2026 - Strong revenue growth and clinical validation position for continued expansion in urology diagnostics.MDXH
Corporate presentation - Revenue up 20% in 2025; 2026 guidance targets $137-140M on expanded urology menu.MDXH
Corporate presentation - 2026 guidance targets 27–30% revenue growth and 10% EBITDA margin, driven by ExoDx integration.MDXH
Q4 2025 - Precision diagnostics firm seeks up to $200M in shares amid ongoing losses and market risks.MDXH
Registration Filing - Q3 revenue up 21%, guidance raised to $87–89M, and cash strengthened by equity financing.MDXH
Q3 2024 - Q2 revenue up 32% to $22.2M, with raised 2024 guidance and strong test volume growth.MDXH
Q2 2024
Next MDxHealth earnings date
Next MDxHealth earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)